Patients who are weighing Sublocade against daily Suboxone are usually asking a version of one question: is the monthly injection actually better, or is it just newer? The honest answer is that both are effective buprenorphine therapies with strong evidence behind them, and the choice between them comes down to how each one fits the individual in front of us. This page walks through the mechanisms, the head-to-head clinical trial data, the lifestyle tradeoffs, and the candidacy framework we use with patients in Chattanooga, Cleveland, Soddy-Daisy, and Ringgold.
How each medication works
Suboxone and Sublocade both contain buprenorphine as the active medication. Buprenorphine is a partial opioid agonist that occupies the same receptors fentanyl, heroin, and prescription opioids bind to, without producing the same euphoric effect. It relieves withdrawal, suppresses cravings, and blocks the reward from other opioids taken on top of it. The two medications differ in what is bundled with the buprenorphine and, more importantly, in how and how often it reaches your body.
Suboxone: daily sublingual film or tablet
Suboxone combines buprenorphine with naloxone, an opioid blocker included specifically to deter intravenous misuse. Taken as directed under the tongue, the naloxone is not absorbed in a meaningful way; if someone tried to inject the medication, the naloxone would trigger precipitated withdrawal. Patients take Suboxone once or twice daily, in doses typically ranging from 8 mg to 24 mg per day. Onset is within 30 to 60 minutes; the effective duration covers about 24 hours when dosed consistently. The medication is dispensed at a pharmacy and taken at home. See our Suboxone treatment page for the full clinical picture.
Sublocade: monthly subcutaneous injection
Sublocade is buprenorphine alone, formulated as a depot injection given once a month under the skin of the abdomen. It does not contain naloxone because the route of administration makes intravenous misuse impossible; the medication forms a solid depot on contact with body fluids. The first two injections are typically given at 300 mg; maintenance continues at 300 mg or steps down to 100 mg depending on clinical response. The depot releases buprenorphine at a steady rate over 28 to 30 days, producing a flat plasma concentration curve rather than the peaks and troughs of daily dosing. The injection is administered at the clinic; the patient takes nothing home. See our Sublocade treatment page for dosing details and the first-visit protocol.
Brixadi: the third option worth knowing about
Patients deciding between Suboxone and Sublocade often do not realize there is a third extended-release buprenorphine option. Brixadi is also a subcutaneous injection, but it offers weekly, every-other-week, and monthly schedules rather than monthly only. Brixadi reaches therapeutic levels faster than Sublocade, does not require the same seven-day transmucosal induction window, and may fit patients who want the adherence advantage of an injection alongside more frequent clinic check-ins. Any conversation about injectable buprenorphine at Restoration Recovery includes Brixadi as a legitimate option, not a second-choice alternative.
What the clinical trials actually show
Clinical trial evidence for both medications is robust. The relevant question for this comparison is what happens when you put the monthly injection head-to-head against standard daily buprenorphine care. Three studies shape the current evidence base.
The EXPO trial: head-to-head superiority
The EXPO trial (Marsden et al., 2023, eClinicalMedicine) is the first effectiveness superiority randomized controlled trial comparing extended-release buprenorphine to daily standard-of-care medication. It enrolled 314 patients with opioid use disorder across five community-based NHS clinics in England and Scotland and followed them for 24 weeks. Patients were randomized to either monthly Sublocade or daily standard-of-care medication.
On the primary endpoint, opioid abstinence days over 24 weeks, patients on Sublocade averaged 123.4 days compared with 104.4 days on daily standard of care, a 19-day advantage (IRR 1.18; 95% CI 1.05 to 1.33; p=0.004). Retention was also higher: 144.6 days versus 128.5 days (p=0.029), and the hazard ratio for time to treatment discontinuation was 0.46 (p<0.001) in favor of Sublocade. At 24 weeks, 75 percent of the Sublocade group met criteria for opioid use disorder remission compared with 62 percent on daily care (OR 1.90; p=0.042). The craving finding is the most striking: 92 percent of Sublocade patients reached a zero craving score on the opioid Craving Experience Questionnaire, compared with 54 percent on daily care (OR 3.22; p=0.001).
The Haight 2019 PROBE trial: buprenorphine injection vs. placebo
The foundational efficacy trial for Sublocade was Haight et al., 2019, published in The Lancet. This was a 24-week, placebo-controlled, double-blind phase 3 trial of 504 adults with moderate or severe opioid use disorder. Participants received either Sublocade 300/300 mg monthly, Sublocade 300/100 mg monthly, or placebo injections, all paired with weekly individual drug counseling. Abstinence rates were 41.3 percent and 42.7 percent in the two Sublocade arms compared with 5.0 percent on placebo (p<0.0001). Treatment success, defined as opioid-free for at least 80 percent of weeks over the 24-week trial, was 29.1 percent and 28.4 percent in the active arms versus 2.0 percent on placebo. Retention was nearly twice as high with Sublocade as with placebo.
Durability at 12 months
Long-term safety and efficacy data come from the Andorn et al., 2020 open-label extension, which followed 669 patients on monthly Sublocade for up to 12 months. Patients who started Sublocade fresh (de novo) achieved a 75.8 percent abstinence rate, and retention at 12 months was 50.5 percent across groups. Most treatment-emergent adverse events were mild and concentrated in the first few injections; pain scores at the injection site dropped from a mean of 44.0 out of 100 after the first injection to 24.7 after the twelfth, suggesting patients adapt to the injection experience over time.
What this evidence does not mean
The head-to-head edge favoring Sublocade is real but narrow, and it is driven largely by adherence. If you can and will take a daily dose of Suboxone consistently, the medications converge on outcomes; missed doses are what widen the gap. The EXPO trial reported one finding that supports this reading directly: in the subgroup of patients with severe baseline opioid use disorder or treatment duration longer than 28 days, Sublocade economically dominated daily care. In patients who were already stabilized and engaged, the two approaches performed closer to each other. Daily Suboxone is not a lesser medication; it is a medication whose effectiveness depends on a consistent daily ritual that some patients find easy and others find difficult.
Daily life on each medication
The pharmacology is half the picture. The other half is what treatment feels like from inside a normal week.
What daily Suboxone looks like
On Suboxone, the day includes one or two sublingual doses taken at consistent times, typically morning and evening. The film or tablet dissolves under the tongue over several minutes; eating and drinking are limited during and immediately after. Patients carry medication when they travel and fit dosing into work schedules, childcare, and sleep. Dose adjustments are relatively straightforward because the medication is short-acting enough to respond within a day or two. Clinic visits during stable maintenance happen at least every two months under BESMART program rules; counseling sessions are typically monthly. The rhythm of treatment is built into daily life, which some patients find stabilizing and others find burdensome.
What monthly Sublocade looks like
On Sublocade, treatment happens in concentrated visits rather than distributed daily rituals. Once stabilized, a patient comes to the clinic once a month, spends 15 to 30 minutes for the injection and a brief clinical check-in, and leaves with nothing to carry. Blood levels stay flat across the month, which smooths out the peaks and troughs of daily dosing and tends to produce a more consistent craving and mood profile. There is no bottle in the medicine cabinet, no pharmacy trip, no explanation owed to family or coworkers. The tradeoff is that patients cannot adjust their own dose on a hard day; the clinical floor for the month is set at the injection.
Lifestyle factors patients actually raise
Patients choose between these medications for reasons that are not strictly clinical. Travel matters: long-haul drivers, shift workers, and patients who spend stretches of time away from home often find monthly Sublocade simpler than carrying a controlled substance across state lines. Privacy matters: patients in shared housing, patients with small children at home, and patients with family members in active use frequently prefer not to keep buprenorphine in the house. Attitudes toward needles matter in both directions; some patients find the one-monthly-poke trade appealing, while others cannot tolerate injections and stay on the daily film for that reason alone. Trust matters: patients who have learned not to trust themselves with medication often feel relief at handing that logistic over to the clinic, while patients who have rebuilt self-trust over time may prefer the autonomy of daily self-administration. None of these preferences are wrong. They are real inputs to a real decision.
Cost and coverage in 2026
Insurance math for these two medications looks different because they are billed through different channels. Suboxone is a pharmacy-benefit medication filled at retail; Sublocade is a medical-benefit medication administered at the clinic and billed as a provider-administered drug.
Sublocade out-of-pocket costs
The current manufacturer list price for Sublocade is approximately $2,202 per month for either the 100 mg or 300 mg dose. Very few patients pay anywhere near that number. According to the manufacturer's own cost savings program data, nearly 90 percent of Medicaid patients pay $0 and the remainder pay $1 to $4 per month. Among commercially insured patients enrolled in the Sublocade Copay Assistance Program, 95 percent pay $0 out of pocket; the program covers medication cost only and is available to privately insured patients, not those on Medicaid or Medicare. Medicare patients see a wide range from $0.02 to $1,607 per dose with an average of $97. About 88 percent of insured Americans have some form of Sublocade coverage.
Suboxone out-of-pocket costs
Generic buprenorphine/naloxone is significantly cheaper than brand Suboxone and is the preferred formulation on most formularies. For TennCare members, preferred generics have no prior authorization requirement at BESMART-enrolled providers for doses up to 24 mg per day. For commercially insured patients, generic buprenorphine/naloxone typically costs $10 to $30 per month with insurance; without insurance, discount pricing through major pharmacy chains often brings the cash price into the $100 to $200 per month range depending on dose.
TennCare specifics
TennCare covers both medications. Sublocade is on the medical benefit with prior authorization, typically requested through a BESMART-enrolled provider. Suboxone (preferred generic) is on the pharmacy benefit and requires no prior authorization at BESMART providers for standard doses. For the complete picture of what TennCare covers for MAT and how BESMART removes coverage friction, see our pillar guide on TennCare coverage for medication-assisted treatment. For commercial plans, see our insurance page for in-network carrier details.
Who is a better candidate for each
After walking hundreds of patients through this decision, certain patterns are consistent enough to name. The framework below is not a diagnostic tool; it is a starting point for the conversation a patient and a physician have together.
Sublocade may fit better if
Monthly injection tends to be the stronger fit for patients with a history of missed Suboxone doses despite good intentions, relapse patterns that cluster around periods of unsupervised medication access, unstable housing or privacy concerns that make keeping medication at home difficult, work schedules that take them away from home for stretches longer than a typical prescription refill, or readiness to simplify treatment after one or two stable years on daily Suboxone. The EXPO trial finding on severe baseline opioid use disorder is worth weighing here: patients entering treatment with longer use histories or heavier daily use may see the largest absolute benefit from the steady plasma levels Sublocade produces.
Suboxone may fit better if
Daily sublingual treatment tends to be the stronger fit for patients who are new to buprenorphine treatment (everyone begins on transmucosal buprenorphine regardless of long-term plan), patients with significant needle anxiety, patients who need dose flexibility for co-occurring conditions like chronic pain, patients who live in rural areas and cannot reliably reach a monthly clinic appointment, and patients who prefer the autonomy of home-based self-management. Some patients describe daily dosing as a useful ritual that reinforces their recovery; for them, taking away that ritual feels like losing something important. That is a legitimate reason to stay on the film.
Brixadi may fit better if
The weekly option makes Brixadi a useful middle path. It tends to fit patients who want the adherence advantage of an injection but prefer more frequent contact with the clinic, patients who need faster time to stable dose than Sublocade's seven-day induction window allows, or patients whose insurance coverage favors Brixadi over Sublocade. For patients switching from daily buprenorphine, Brixadi's induction requirements are less strict than Sublocade's, which can shorten the overall transition timeline.
It is not a one-way door
Patients switch between Suboxone and Sublocade in both directions, and both transitions are clinical routine when they are managed by the clinic. Moving from Suboxone to Sublocade requires at least seven days of stable transmucosal buprenorphine dosing between 8 and 24 mg per day, per FDA labeling. Moving from Sublocade to Suboxone is typically timed around the next scheduled injection date, since the depot continues releasing buprenorphine for about 28 to 30 days after the last dose. A common and clinically appropriate pathway is one to two years of stability on daily Suboxone followed by a transition to Sublocade for simplified maintenance. The reverse is equally legitimate when lifestyle changes, insurance changes, or injection site tolerance argue for daily dosing.
Safety and side effects
Most common side effects overlap across both medications because the active medication, buprenorphine, is the same. Constipation, headache, nausea, and fatigue are the frequent complaints on both; they typically lessen over the first few weeks and respond to standard supportive care.
Sublocade-specific safety considerations
Sublocade's defining safety consideration is the injection itself. Injection site reactions occurred in roughly 16 percent of patients new to Sublocade in the 12-month extension study; most were mild and decreased in frequency and severity with repeated injections. Rare post-marketing case reports describe more serious reactions including abscess, ulceration, and in a small number of cases tissue necrosis; the FDA labeling notes that risk of serious reactions rises with inadvertent intramuscular or intradermal administration, which is why only trained clinicians deliver the injection. Sublocade carries a boxed warning against intravenous administration: the depot forms a solid mass on contact with body fluids, and IV administration could cause pulmonary embolism. This is a clinical-setting-only medication for that reason.
An important counterweight in the EXPO data: while minor adverse event rates were higher on Sublocade (81 percent versus 43 percent for daily care, mostly mild injection-related events), serious adverse event rates were actually lower (7 percent versus 11.5 percent). More minor events, fewer serious ones.
Suboxone-specific safety considerations
Daily buprenorphine's main acute safety consideration is precipitated withdrawal during induction if the medication is started too soon after the last full-agonist opioid dose. This is managed with a COWS-scored induction protocol that waits for early withdrawal to establish before the first dose. Chronic concerns include dental issues reported with long-term sublingual dosing; rinsing with water after the dose dissolves reduces this risk. Drug interactions with benzodiazepines and other central nervous system depressants require careful medication reconciliation for both Suboxone and Sublocade.
How we decide together at Restoration Recovery
Restoration Recovery's four-step first-visit flow is designed to make this decision a joint one rather than a provider-assigned one. The first visit includes a DSM-5 assessment and, for opioid use disorder, a COWS withdrawal score; a counseling conversation that surfaces the lifestyle and preference factors named above; a physician visit where the clinical and personal factors come together; and a treatment plan that includes the first prescription or injection order. The sequence matters: the counselor's notes inform the physician's conversation, which informs the medication decision.
We do not push patients toward one medication or the other. Both Suboxone and Sublocade (and Brixadi, for patients who want to weigh it) are covered by TennCare and by most commercial plans we contract with. Our job is to lay out the evidence clearly, understand what your life actually looks like, and help you choose the treatment you are most likely to stay engaged with. Staying engaged is what produces recovery; the specific formulation is a tool for getting there.
Common questions patients ask
Is one medication more effective than the other?
Head-to-head evidence gives monthly Sublocade a modest edge on abstinence, retention, and craving reduction, driven largely by adherence. In the EXPO trial, patients on Sublocade averaged 19 more opioid-free days over 24 weeks than patients on daily buprenorphine, and 92 percent reached zero craving versus 54 percent on the daily oral medication. Both medications work; the gap widens for patients with adherence challenges or severe baseline opioid use disorder.
Can I switch between Sublocade and daily Suboxone?
Yes, in both directions. FDA labeling requires at least seven days on transmucosal buprenorphine at 8 to 24 mg per day before the first Sublocade injection. Going from Sublocade back to daily Suboxone is typically done on or around the next scheduled injection date; the depot continues releasing buprenorphine for about 28 to 30 days, so the handoff is smooth when the clinic plans it.
What if I have a needle phobia?
Most patients who start Sublocade with needle concerns tolerate the injection well. It goes under the skin (not into a vein), one site per month, and clinical trial data show pain scores drop substantially after the first few doses. That said, needle fear is a real reason to stay on daily Suboxone or choose Brixadi, which offers a weekly schedule with smaller injections.
How soon after my first visit can I start Sublocade?
FDA labeling requires a minimum of seven days on transmucosal buprenorphine at a stable dose between 8 and 24 mg per day before the first Sublocade injection. Patients are monitored for one hour after the first injection to confirm tolerability. Some clinics offer accelerated protocols for high-risk patients; at Restoration Recovery, we follow the FDA-approved standard unless specific clinical circumstances support faster initiation.
What happens if I miss a Sublocade appointment?
The depot continues releasing buprenorphine for about 28 to 30 days, so being a few days late is not a crisis. Longer gaps risk the return of cravings and withdrawal symptoms. Call the clinic as soon as you know you will miss an appointment; most of the time the visit can be rescheduled within a few days without losing coverage.
Will insurance cover both medications?
TennCare covers preferred generic buprenorphine/naloxone without prior authorization at BESMART-enrolled providers for doses up to 24 mg per day. Sublocade is covered under the TennCare medical benefit with prior authorization because it is administered in the clinic rather than filled at a pharmacy. Commercial insurance coverage varies; Sublocade offers a copay assistance program that brings 95 percent of privately insured patients to zero out-of-pocket cost.
Do I need to be abstinent before starting Sublocade?
You do not need to be fully abstinent from opioids before starting treatment. You do need to be past acute withdrawal and stabilized on daily transmucosal buprenorphine for at least seven days before the first Sublocade injection. The sequence is COWS-scored induction onto Suboxone on day one, stabilization across the first week, then transition to Sublocade for patients who want to switch.
Is Brixadi a real third option, or just a backup?
Brixadi is a legitimate third option. It is another extended-release buprenorphine injection with weekly or monthly schedules and a faster time to stable dose than Sublocade. For patients who want the adherence advantage of an injection but prefer more frequent clinic check-ins, Brixadi is often the better fit. See our Brixadi treatment page for a full clinical picture.
The choice is real, and it is yours to make
Both Sublocade and daily Suboxone are effective buprenorphine medications backed by substantial clinical trial evidence. The head-to-head data gives monthly Sublocade a modest edge, largely because a medication that cannot be missed outperforms a medication that must be remembered. That edge is real for some patients and almost invisible for others; it depends on how daily dosing fits your life. The decision is a clinical conversation, not a marketing pitch, and both paths lead to recovery when they match the patient.
If you are weighing this decision right now, the next step is the same regardless of which medication you lean toward. Book a first appointment or call 423-498-2000. We will run a COWS-scored induction onto Suboxone on day one, talk through the Sublocade and Brixadi options during your first counseling session, and help you decide over the first week what comes next. Coverage, scheduling, and transitions are our problem, not yours. Starting is.